Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

147
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
147
Teratogenicity01:07

Teratogenicity

4.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.5K
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

161
Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
161
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

3.3K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.3K
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

145
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
145
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

106
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
106

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A telephone intervention to achieve differentiation in dietary intake: a randomized trial in paediatric primary care.

Pediatric obesity·2016
Same author

Registered Replication Report: Schooler and Engstler-Schooler (1990).

Perspectives on psychological science : a journal of the Association for Psychological Science·2015
Same author

Maternal hypertensive disorders, antihypertensive medication use, and the risk of birth defects: a case-control study.

BJOG : an international journal of obstetrics and gynaecology·2014
Same author

Adverse drug reactions in utero: perspectives on teratogens and strategies for the future.

Clinical pharmacology and therapeutics·2011
Same author

Application of pharmacogenomic strategies to the study of drug-induced birth defects.

Clinical pharmacology and therapeutics·2007
Same author

Adult pertussis in a general practice.

Health bulletin·2003

Related Experiment Video

Updated: Mar 23, 2026

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

9.2K

Research challenges for drug-induced birth defects.

A A Mitchell1

  • 1Slone Epidemiology Center at Boston University, Boston, Massachusetts, USA.

Clinical Pharmacology and Therapeutics
|April 3, 2016
PubMed
Summary

Drug-induced birth defects, or teratogenesis, are unique adverse drug reactions (ADRs) affecting a fetus. Identifying teratogens requires specific study designs considering drug, defect, and timing, as fetal safety data is limited for most marketed medications.

More Related Videos

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

88.4K
Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods
08:28

Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods

Published on: March 10, 2020

7.4K

Related Experiment Videos

Last Updated: Mar 23, 2026

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
08:22

A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations

Published on: December 1, 2017

9.2K
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

88.4K
Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods
08:28

Analysis of Congenital Heart Defects in Mouse Embryos Using Qualitative and Quantitative Histological Methods

Published on: March 10, 2020

7.4K

Area of Science:

  • Pharmacology and Toxicology
  • Developmental Biology
  • Reproductive Medicine

Background:

  • Drug-induced birth defects, known as teratogenesis, are distinct adverse drug reactions (ADRs).
  • ADRs manifest in the fetus, not the treated individual, posing unique challenges.
  • Most teratogenic agents are identified only post-market, highlighting a significant knowledge gap.

Purpose of the Study:

  • To underscore the unique challenges in identifying drug-induced birth defects.
  • To emphasize the limited understanding of fetal safety for many marketed drugs.
  • To highlight the necessity of specific study designs for teratogen identification.

Main Methods:

  • Review of existing literature on drug-induced birth defects and ADRs.
  • Analysis of challenges in identifying teratogens.
  • Discussion of critical factors in study design for teratogenicity assessment.

Main Results:

  • Teratogenesis represents a unique class of ADRs with indirect impact.
  • Post-market surveillance is the primary method for identifying teratogens.
  • Current knowledge of fetal drug safety is insufficient for most medications.

Conclusions:

  • Identifying teratogens requires specialized research considering drug, defect, and gestational timing.
  • Further research and improved study methodologies are crucial for assessing fetal drug safety.
  • Proactive identification of teratogens is essential for public health and patient safety.